Blog

Samer Al Hadidi: Prior Exposure to Belantamab Mafodotin with Idecabtagene Vicluecel in Multiple Myeloma

Samer Al Hadidi/LinkedIn

Mar 18, 2025, 10:01

Samer Al Hadidi: Prior Exposure to Belantamab Mafodotin with Idecabtagene Vicluecel in Multiple Myeloma

Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, posted on LinkedIn about recent paper he and colleagues co-authored, titled “Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma” published on American Society of Hematology Blood Advances.

Authors: Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D. Shaughnessy, Jr, Fenghuang Zhan, Eric R. Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi

“Check out recent work published American Society of Hematology Blood Advances.

Prior Exposure to Belantamab, Mafodotin Influences Outcomes with Idecabtagene ,Vicluecel in Patients with Multiple Myeloma.”

American Society of Hematology Blood Advances Bhavesh Mohan Lal cancer Carolina Schinke Eric R. Siegel Fenghuang Zhan Frits Van Rhee Jawad Alrawabdeh John D. Shaughnessy Jr Marah Alzubi Maurizio Zangari multiple myeloma OncoDaily Oncology Samer Al Hadidi Sharmilan Thanendrarajan

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute